Radiation therapy outcomes of patients with pituitary macroadenoma.

IF 2.3 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Sardar Ali Khan, Waqas Shafiq, Umal Azmat, Ahmed Imran Siddiqi, Asim Munir Alvi, Sara Ashfaq, Hira Irfan, Muhammad Abu Bakar, Kashif Asghar
{"title":"Radiation therapy outcomes of patients with pituitary macroadenoma.","authors":"Sardar Ali Khan,&nbsp;Waqas Shafiq,&nbsp;Umal Azmat,&nbsp;Ahmed Imran Siddiqi,&nbsp;Asim Munir Alvi,&nbsp;Sara Ashfaq,&nbsp;Hira Irfan,&nbsp;Muhammad Abu Bakar,&nbsp;Kashif Asghar","doi":"10.3892/br.2022.1594","DOIUrl":null,"url":null,"abstract":"<p><p>Pituitary adenomas are one of the most common benign intracranial tumors, which are normally treated with surgery along with radiation therapy and medication such as dopamine agonist in prolactinoma. The aim of the present study was to evaluate the outcome of patients with pituitary macroadenoma who underwent radiation therapy. For the present retrospective study, a total of 75 patients with pituitary macroadenoma who received radiation therapy were included. Data was acquired from the electronic medical record system of the hospital. Mean ± standard deviation of the quantitative variables, such as age and sizes of the tumors, were reported. In addition, frequencies and percentages were presented for all categorical variables. To compare the frequency distribution in radiation therapy characteristics between functional and non-functional tumors, the χ<sup>2</sup> test or Fisher's exact test was applied, where appropriate. Kaplan-Meier survival curve was drawn to assess the progression free survival proportion. P≤0.05 was considered to indicate a statistically significant difference. In the present study, all patients (n=75) with pituitary macroadenoma were treated with radiation therapy (RT). The mean age was 38.55±1.36 years and the majority of the patients were male (43; 57.3%). The mean tumor size was 3.84±1.43 cm. In total, 66.7% were non-functional tumors whereas 33.3% were functional tumors that produce hormones in excess [growth hormone (72%), prolactin (16%), both growth hormone and prolactin (8%) and adrenocorticotropic hormone (4%)]. The overall outcome was revealed to be 92% achieving local tumor control and 28% achieving biochemical control. Hypopituitarism (38.7%) and visual acuity deterioration (9.3%) were the most common complications observed following RT. The overall progression-free survival at 2 years was 92%. In conclusion, the data of the present study suggested that local tumor control in non-functional and functional pituitary macroadenoma can be well managed with RT. However, biochemical control to normalize hormones overproduction in functional pituitary macroadenoma was not as effective as local tumor control.</p>","PeriodicalId":8863,"journal":{"name":"Biomedical reports","volume":"18 2","pages":"12"},"PeriodicalIF":2.3000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/53/f3/br-18-02-01594.PMC9764322.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3892/br.2022.1594","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Pituitary adenomas are one of the most common benign intracranial tumors, which are normally treated with surgery along with radiation therapy and medication such as dopamine agonist in prolactinoma. The aim of the present study was to evaluate the outcome of patients with pituitary macroadenoma who underwent radiation therapy. For the present retrospective study, a total of 75 patients with pituitary macroadenoma who received radiation therapy were included. Data was acquired from the electronic medical record system of the hospital. Mean ± standard deviation of the quantitative variables, such as age and sizes of the tumors, were reported. In addition, frequencies and percentages were presented for all categorical variables. To compare the frequency distribution in radiation therapy characteristics between functional and non-functional tumors, the χ2 test or Fisher's exact test was applied, where appropriate. Kaplan-Meier survival curve was drawn to assess the progression free survival proportion. P≤0.05 was considered to indicate a statistically significant difference. In the present study, all patients (n=75) with pituitary macroadenoma were treated with radiation therapy (RT). The mean age was 38.55±1.36 years and the majority of the patients were male (43; 57.3%). The mean tumor size was 3.84±1.43 cm. In total, 66.7% were non-functional tumors whereas 33.3% were functional tumors that produce hormones in excess [growth hormone (72%), prolactin (16%), both growth hormone and prolactin (8%) and adrenocorticotropic hormone (4%)]. The overall outcome was revealed to be 92% achieving local tumor control and 28% achieving biochemical control. Hypopituitarism (38.7%) and visual acuity deterioration (9.3%) were the most common complications observed following RT. The overall progression-free survival at 2 years was 92%. In conclusion, the data of the present study suggested that local tumor control in non-functional and functional pituitary macroadenoma can be well managed with RT. However, biochemical control to normalize hormones overproduction in functional pituitary macroadenoma was not as effective as local tumor control.

Abstract Image

垂体大腺瘤患者放射治疗效果分析。
垂体腺瘤是最常见的颅内良性肿瘤之一,其治疗方法通常为手术配合放射治疗和药物治疗,如催乳素瘤的多巴胺激动剂。本研究的目的是评估垂体大腺瘤患者接受放射治疗的结果。本回顾性研究共纳入75例接受放射治疗的垂体大腺瘤患者。数据来自医院的电子病历系统。年龄、肿瘤大小等定量变量的均数±标准差均有报道。此外,给出了所有分类变量的频率和百分比。为了比较功能性肿瘤和非功能性肿瘤放射治疗特征的频率分布,适当时采用χ2检验或Fisher精确检验。绘制Kaplan-Meier生存曲线,评估无进展生存比例。以P≤0.05为差异有统计学意义。在本研究中,所有垂体大腺瘤患者(n=75)均接受放射治疗(RT)。平均年龄38.55±1.36岁,男性居多(43;57.3%)。平均肿瘤大小为3.84±1.43 cm。其中66.7%为非功能性肿瘤,33.3%为分泌过量激素的功能性肿瘤[生长激素(72%)、催乳素(16%)、生长激素和催乳素兼用(8%)和促肾上腺皮质激素(4%)]。总体结果显示,92%达到局部肿瘤控制,28%达到生化控制。垂体功能减退(38.7%)和视力下降(9.3%)是放疗后最常见的并发症。2年总无进展生存率为92%。综上所述,本研究的数据表明,非功能性和功能性垂体大腺瘤的局部肿瘤控制可以通过rt得到很好的控制。然而,功能性垂体大腺瘤通过生化控制使激素分泌过剩正常化不如局部肿瘤控制有效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Biomedical reports
Biomedical reports MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
4.10
自引率
0.00%
发文量
86
期刊介绍: Biomedical Reports is a monthly, peer-reviewed journal, dedicated to publishing research across all fields of biology and medicine, including pharmacology, pathology, gene therapy, genetics, microbiology, neurosciences, infectious diseases, molecular cardiology and molecular surgery. The journal provides a home for original research, case reports and review articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信